TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) is an oncology-focused medical technology company developing pressure-enabled delivery technology and therapies for solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform modulates vascular pressure and flow to improve delivery of therapeutics into tumors while… From the company’s description.
Over the twelve months to Jun 30, 2026, TriSalus Life Sciences, Inc. reported revenue of $45.08M, up 25.2% from a year earlier, and a net loss of $28.21M. Its operating margin was −67.7%, and operations used $22.80M in cash. In fiscal 2025, it reported revenue of $45.15M, up 53.4% from fiscal 2024, and a net loss of $39.23M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What TriSalus Life Sciences, Inc. does
In the company’s own words
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) is an oncology-focused medical technology company developing pressure-enabled delivery technology and therapies for solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform modulates vascular pressure and flow to improve delivery of therapeutics into tumors while limiting off-target distribution. The company’s principal commercial product, the FDA-cleared TriNav Infusion System, is used by interventional radiologists in procedures including transarterial radioembolization and chemoembolization, mainly for primary liver cancer and liver metastases; customers include hospitals and ambulatory surgery centers. TriSalus also markets TriNav for selected non-malignant embolization procedures and has developed the FDA-cleared but not yet commercialized PRVI device for pancreatic tumor infusion. Its investigational drug nelitolimod, a TLR9 agonist, is being studied with PEDD in liver and pancreatic cancers. The company reports one business centered on its medical technology and therapeutic platform. TriNav generated $45.2 million in revenue in 2025, and PEDD had been used in more than 31,000 procedures. TriSalus acquired worldwide rights to nelitolimod from Dynavax in 2020. Its website is https://trisaluslifesci.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- WESTMINSTER, CO
- Fiscal year end
- December
- CIK
- 1826667
- SIC
- 3841
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns TriSalus Life Sciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · TriSalus Life Sciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do TriSalus Life Sciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of TriSalus Life Sciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in TriSalus Life Sciences, Inc.'s last four quarterly filings that the numbers alone won't show?”